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Currently, melanoma of uvea is the most well-known essential tumor, which is 
intaocular and malignant. Treatment using radiation has now supplanted enucle-
ation as the therapy of decision. Radioactive eye plaques and treatment using 
proton are being the two most examined radiotherapeutic modalities. All the more 
as of late, stereotactic radiosurgery and fractionated stereotactic radiotherapy have 
risen as promising, non-intrusive medicines for uveal melanoma. Technique called 
stereotactic radiosurgery might be viewed as like “not surgery” on the grounds no 
extractions are included. All things being equal, it is a serious strategy for radiation 
treatment that conveys high dosages of radiation to exceptionally little territories 
and volumes.
Keywords: intraocular tumor, uveal melanoma, radiotherapy, stereotactic 
radiosurgery
1. Introduction
Malignant melanoma of uvea (iris, ciliary body, and choroid), is the most widely 
recognized essential intraocular danger in grown-ups. Uveal melanoma (UM) is 
analyzed generally in more established age, with a dynamically increasing age-
explicit frequency rate that tops close to the age of seventy. Ocular melanoma is 
probably going to metastasize in different lregions of the body, for example, breast, 
lung, kidney or liver.
There are many factors associated with the development of uveal melanoma. The 
most important include genetic factors, race, color of the eyes, fair coloring of the 
skin and the ability to tan. Many observational studies up to date have attempted 
to explore the relationship between sunlight exposure and risk of uveal melanoma 
development [1].
Usually, uveal melanomas are in early stages of their development completely 
asymptomatic. The comparatively low incidence of iris melanomas (anterior seg-
ment melanoma) has been attributed to the characteristic features of these tumors. 
Iris melanomas also rarely metastasize. Posterior melanoma - choroidal melanoma 
is the most common ocular melanoma type. This type is involved in over 75% of all 
intraocular melanomas. Iris melanoma wchis is in anterior segment is cytologically 
less malignant and metastatize less frequently tnak posterios uveal melanomas.
Ordinarily, choroidal melanoma is brown colored, raised mass, and the level of 
its pigmentation can go from dim earthy colored to thoroughly white, amelanotic.
In advanced stages the symptoms are dependent on tumor location. The most 
important test to establish the presence of intraocular melanoma, is the examination 
by an experienced clinician at specialized Ophthalmology Department. Diagnostic 
testing can be extremely valuable in establishing and confirming the diagnosis.
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Prognosis can be influenced by number of factors. The most important are the 
histopathologic type of cells, the size of tumor, tumor volume, the margins of the 
tumor, karyotype and grading and staging by TNM Classification (e.g. extraocular 
extension). Cell type, however, remains the most often used predictor of outcome 
with genetic results.
The treatment relies upon the site of birthplace (choroid, ciliary body or iris), the 
size, volume and area of the injury, the general statis of the patient, age of the patient 
and whether extraocular attack, repeat or metastasis has happened. Extraocular 
augmentation, repeat, and metastasis are related with a very helpless guess and long - 
term endurance cannot be normal [2].
Elective therapy modalities have been proposed as of late including extremist 
careful evacuation of the eye globe (enucleation), nearby resection, light proce-
dures: plaque brachytherapy, charged-molecule radiotherapy, stereotactic photon 
bar illumination treatment or in start of the tumor transpupillary thermotherapy 
and photodynamic treatment.
Over the past 3–4 decades diagnostic methods have improved and radiotherapy 
(external beam, charged particle or brachytherapy) has become the preferred treat-
ment for most of the patients with uveal melanoma. The aim of the treatment is to 
improve survival and preserve eye globe anatomically with aim to preserve the best 
vision in patients with uveal melanoma. Different radiation modalities are currently 
in use in treatment of posterior uveal melanoma in many Ophthalmology Centers. 
One of the methods of “conservative” approach is the stereotactic radiosurgery 
(SRS) by linear accelerator [2–5].
2. Uvea and uveal tumors
The uveal parcel frames the center layer (or “vasculo-strong” coat) mass of the 
eyeball. Uvea layer is a combination of veins, pigmented cells and muscles, woven 
together by connective tissue. It has a nutritive capacity of the eye globe. The uveal 
parcel comprises of three anatomical parts, all profoundly vascular and pigmented. 
The noticeable part in front is the iris (part of the foremost portion of the eye) and 
it makes the shade of the eye globe. The iris consolidates in reverse into the ciliary 
body, and the ciliary body offers path to the choroid, to the back fragment of the eye 
globe, which is such a vascular undercoat between the sclera and the shade retina. It 
is substantial pigmented, along these lines engrossing light which has gone through 
the retina.
2.1 Uvea layer
The pigmented cells (the melanocytes) - are derived from the neural crests 
which have migrated to the skin and mucous membranes. Melanocytes synthesize 
a special organelle called a melanosome – this is responsible for the characteristic 
color of the skin in different races. Melanosis (melanocytosis) refers to increased 
pigmentation caused by hyperplasia or hypertrophy of melanocytes.
Changes in melanocytes usually cause melanomas. Melanocytes produce mela-
nin, which is responsible for skin and hair tone. It can show up on ordinary skin or it 
might start as a mole or other territory that has changed in appearance. A few moles 
that are available upon entering the world may form into melanomas during the 
adulthood.
Benign tumor composed of nevus cells or melanocytes is nevus. In nevi cells 





Melanoma is a malignant tumor resulting from a transformation of melanocytes 
or nevus cells. It may be pigmented or non-pigmented. Melanoma is caused mainly 
by intense, occasional UV exposure (frequently leading to sunburn), especially in 
those who are genetically predisposed to the disease. Most melanomas are dark or 
earthy colored, however they can likewise be skin-shaded, pink, red, purple, blue 
or white. In the event that melanoma is perceived and treated early, it is quite often 
reparable, however on the off chance that it is not, the tumor can progress and 
spread to different pieces of the body, particularly liver, where it turns out to be 
difficult to treat and can be deadly. Melanomas frequently metastasize widely and 
the regional lymph nodes, liver, lungs and brain are likely to be involved.
Intraocular melanoma is the most common primary ocular malignant tumor in 
adults and develops from uvea. Intraocular tumors might be benign or malignant.
Intraocular melanoma is a quite rare type of tumor and it occurs most often in 
elderly people. There is lot of cases when ophthalmologists detected intraocular 
melanoma during a routine eye examination. The chance of recovery is depend-
ing on factors such as the size, localization and cell type of the tumor. Extraocular 
extension is the term used to describe the intraocular melanoma which spreads to 
the optic nerve or nearby tissue of the eye socket and is the sign of the advanced 
stage of the tumor [6].
Intraocular melanoma of the ciliary body and choroid (structures together 
called the posterior uvea), is the most common primary ocular malignant tumor 
in adults. Iris melanomas are a subset of uveal melanomas that tend to have a more 
benign course, in comparison with posterior uveal melanomas. Anterior segment 
melanomas have a lower incidence of metastases when compared to ciliary body 
and choroidal melanomas. Anterior segment melanomas account for about 15% 
of all uveal melanomas. The incidence of uveal melanoma increases with age and 
reaches a maximum between the 6th and 7th decade of life. It is more common in 
males and is uncommon or rare in kids and darker looking people. Uveal mela-
nomas are infrequently two-sided. Be that as it may, the quantity of patients with 
two-sided inclusion is more noteworthy than would be anticipated by chance alone, 
subsequently inferring a potential hereditary inclination.
As mentioned before, choroidal melanoma represents the most common primary 
intraocular tumor in adults. Peak incidence is in the early 60s representing about 
7.5 cases per one million populations. Incidence is rare in younger adults under 
30 years of age with an estimated peak incidence of about six cases per one hundred 
million. Caucasians are 8 times more likely to develop the melanoma than Africans 
or Afro-Americans and 3 times more likely than Asians. Intraocular melanoma is 
arising from choroid in more than 75% of all the cases. Whether some environmen-
tal exposure triggers the development of uveal melanoma remains an open question. 
Sunlight has been proposed as an environmental risk factor for melanoma generally. 
Unlike cutaneous melanoma, incidence rates for uveal melanoma have not increased 
over time and last decades and it does not vary by latitude [7, 8].
2.3 Diagnostic method of uveal melanoma
The first step to diagnose uveal melanoma is patient’s history. Patients with uveal 
melanoma may present with complaints of visual acuity reduction, but many can be 
without symptoms and the condition is discovered on routine ocular examination 
or by glasses prescription. In eyes with clear optic media, the diagnosis of posterior 
uveal melanoma can be made by indirect ophthalmoscopy.
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a. ophthalmoscopy, fundus photography,
b. transillumination,
c. perimetry,
d. fluorescein angiography, indocyanine green angiography,
e. ultrasonography (A and B modes),
f. ultrasound biomicroscopy - UBM,
g. optical coherence tomography - OCT,
h. computed tomography - CT,
i. magnetic resonance imaging - MRI,
j. fine-needle biopsy
k. whole body PET/CT to distinguish metastasis.
Depending on their site of growth, posterior uveal melanomas differ in their 
symptoms, clinical presentation and appearance. A ciliary body melanoma can 
attain a large size, volume, before it is clinically recognized. It can be seen in 
association with one or more dilated episcleral blood vessels, it can present itself 
as an epibulbar pigmented lesion if there is transscleral extension of the tumor. 
Also, cataract, and/or lens subluxation or secondary glaucoma due to infiltration 
of the trabecular meshwork in the angle of the eye can be present. The tumor can 
be envisioned clinically through a broadly enlarged understudy by cut light assess-
ment as an arch formed collection in the area or it can have a diffuse circumferential 
development design known as “ring melanoma”. It can develop anteriorly into the 
front chamber – iridocorneal point and iris (iridociliary melanoma) or back into the 
choroid (ciliochoroidal melanoma).
A melanoma of choroid ordinarily presents as a sessile or curve formed col-
lection arranged under the retina. Initial step analytic techniques can be aberrant 
ophthalmoscopy, ultrasound and fluorescein angiography. Surface orange color at 
the degree of the retinal shade epithelium can be imagined clinically, particularly 
in more modest back melanomas. Retinal separations can be seen auxiliary to the 
tumor development just as Bruch membrane rupture (cellar layer bellow the retinal 
shade epithelium). We can divide melanoma of chodoid into two groups the first is 
melanoma with pigment and the second one is melanoma withou pigment and can 
likewise accept a spread development design with just negligible tumor diameter 
under 3 mm.
Melanoma of ciliary body and melanomas of choroidea may develop cataracts, 
extraocular extension, secondary glaucoma. Orbital infiltration can be seen usually 
when the tumor has large volume, higher stage and they therefore have a worse 
prognosis [9].
Due to the huge range of clinical, morphologic and cytological changes and an 
absence of discrete stages it is hard to foresee clinical result in singular instances of 
uveal melanoma based on intraocular tumor size. His size and volume is perhaps the 




A little tumor - melanoma - is characterized as estimating 3 mm or less in 
thickness and under 10 mm in breadth because of TNM plot. A tumor is delegated 
medium-sized in the event that it measures between 3 to 5 mm in thickness and 
between 10 to 15 mm in width. A huge tumor is more prominent than 5 mm in 
thickness and in excess of 15 mm in breadth.
Patients, who are diagnosed with a primary choroidal “intraocular” melanoma, 
have usually no signs or symptoms of metastatic tumor. Even with total body 
positron emission tomography/computed tomography (PET/CT) imaging, very 
few patients are found to have their melanomas spread to other parts of their body. 
Others may be found to have metastasis over the following years. The overall percent-
age of the patients diagnosed for choroidal melanoma does not develop metastatic 
melanoma. The size of the tumor is one of the very important factors to predict the 
risk for metastatic spreading. Treatments that limit tumors ability to enlarge will 
decrease the chance of metastasis because removing the eye tumor is the best method 
to prevent future spread from that tumor. It is very important for the patients to have 
periodic general medical examinations because the treatment itself does not affect 
micrometastasis that can be already present at the time the treatment occurs.
Patients who have metastatic choroidal melanoma, as mentioned above, seem 
to have no symptoms. For this reason, they should have periodic medical examina-
tions, physical examinations, blood tests and radiographic imaging tests as X-ray, 
MRI, CT or PET/CT. Later on, patients may have symptoms like loss of their 
appetite, difficulty with breathing or fatigue.
The highest percentage of metastatic choroidal melanoma is likely to be found 
in the liver. Metastases in this area of the body can be discovered by blood tests or 
abdominal imaging studies even in cases when patients are asymptomatic. Besides 
this, other organs also can be affected, e.g. subcutaneous lymph nodes, lung, bone 
and brain. A needle biopsy can be used to aspirate tumor cells for cytopathologic 
examination, when a liver or skin metastasis is suspected.
The liver is the known site of metastasing of choroidal melanoma. Hepatic 
enzyme levels are tested in all patients with melanoma of uvea. The most sensitive 
tests of liver capacity are serum antacid phosphate levels, glutamate oxaloacetic 
transaminase, lactate dehydrogenase and gamma-glutamyl transpeptidase. These 
test results are negative at closure hour in the majority of patients with choroidal 
melanoma. If any of the results of these research devices is anomalous, ultrasonog-
raphy and CT of the liver are displayed. Both imaging modalities have low suscepti-
bility to metastases with a diameter of less than 10–20 mm [10–13].
2.4 Survival modeling of intraocular melanoma
Endurance displaying gives a sign of guess. Likewise, it empowers exceptional 
measures to be focused just as it improves the assessment of clinical methodology.
Endurance rates give a more precise system so as to depict the visualization for 
patients with a specific stage and type of disease. These rates are frequently founded 
on past results of huge quantities of individuals who had the sickness, however 
they cannot anticipate what will occur in a specific patient’s case. In patients whose 
malignancy is bound to the eye, the five-year endurance rate is about 80%. This is 
as opposed to melanomas that have spread to inaccessible pieces of the body, where 
the five-year endurance rate is about 15%.
2.4.1 Prognostic factors for uveal melanoma
Pigmented choroidal lessions that are somewhat raised might be called vague 
sores and present a test concerning determination and the board. Given the dangers 
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and restrictions regarding getting histological affirmation of harm, ophthalmolo-
gists need to depend on clinical qualities recognized as prescient of development 
and metastasis so as to separate little melanomas from raised choroidal melanocytic 
tumors that are likely kindhearted. Shields et al. distinguished five components 
related with danger of development of little choroidal melanocytic lessions under 
3 mm in diameter using examinations retrospectively of around 1300 patients [14].
These factors were:
1. posterior tumor margin touching the disc;
2. visual symptoms;
3. tumor thickness bigger than 2.0 mm;
4. subretinal fluid;
5. orange pigment.
In 4 percent of patients was observed growth of lesion with none of risk factor, 
in 36 percent of patients was present one risk factor, and three or more factors were 
present in more than 50 percent of patients.
Clinical factors associated with an increased risk of metastasis included:
1. growth documentation;
2. increased tumor diameter (bigger than/equal to 1.1 mm);
3. posterior margin touching the disc.
The small-tumor observational study conducted by the COMS Group identified 
similar risk factors associated with tumor growth; namely
1. apical tumor thickness was greater,
2. initial basal diameter was larger,
3. orange pigment was present,
4. there were no drusen,
5. retinal pigment epithelial change adjacent to the tumor was absent.
Prognostic factors for uveal melanoma can be subdivided into three categories: 
clinical, histopathological and genetical. Clinical predictive factors have been 
extensively described. Location of the tumor, its thickness and diameter are clinical 
factors predicting tumor growth. In addition, age at time of treatment, male gender 
and secondary glaucoma were prognostic relevant. Shields constructed a mnemonic 
“TFSOM” “to find small ocular melanoma” (thickness greater than 2 mm, subreti-
nal fluid, symptoms, orange pigment and margin at the disc) to assist in identifying 
small choroidal melanoma at risk for growth. The most important histopathological 
markers predicting clinical behavior are the presence of epithelioid cells, largest 
tumor diameter, sclera invasion, and presence of vascular loops. Other valuable 




lymphocytes. The cell sort of uveal melanoma is identified with guess. Patients 
with tumors made out of unadulterated axle cells have a more ideal guess, and 
those with a part of epithelioid cells (blended or epithelioid-cell types) have a more 
awful  visualization. Melanomas with a low mitotic movement show a superior 
anticipation. Tumor invasion by lymphocytes has been related with diminished 
 endurance [15].
3. Overview of methods of treatment of uveal melanoma
These days there are a lot greater treatment choices other than enucleation, 
which was the main alternative for a large portion of a century ago. The more mod-
erate treatment choices mean to save the influenced eye and hold vision. Treatment 
of uveal melanoma relies upon different variables including age of the patients, 
foundational strength of the patient, state of the contrary eye, tumor size and area.
Neverthesess, metastases cannot be prevented. Based on the theoretical models, 
clinically manifest metastases are likely to occour 5 or 6 years onset of the systemic 
dissemination. By the time we diagnosis uveal melanoma, micrometastases may 
have been spread as of now. Along these lines, metastatic sickness happening after 
therapy is not unprecedented. Roughly 50% of the patients will kick the bucket 
from the sickness inside 10 to 15 years of enucleation. When a metastasis is found 
the endurance is under 7 months. In the event that a metastasis emerges as a lone 
injury in the liver, expanded endurance might be acquired by nearby resection of 
the tumor mass.
Tumor area and size are considered to be two of the primary factors in deciding on 
the treatment of ocular melanoma. There is no reason to save the eye if a small mela-
noma in a necessary place completely destroyed vision. It is important to remember 
this - patients who have undergone enucleation and individuals who have undergone 
radiation treatment respond appropriately when they receive information about the 
nature of their patients after treatment. The most important for them was tumor 
endurance.
Treatment using radiation is a typical therapy for intraocular melanoma that 
utilizes high energy radiation to kill tumor cells. Radiation treatment can regularly 
safeguard some vision, albeit once in a while this is lost at any rate since radiation 
harms different pieces of the eye. The structure of the eye is saved and this is mainly 
the advantage of this sort of treatment.
Radiation treetment can be divided into two categories. External radiation 
treatment that utilizes a machine outside the body to send radiation toward the 
tumor, and the second type is inside radiation treatment that utilizes a radioactive 
substance fixed in needles, seeds, wires, or catheters that are set legitimately into or 
close to the tumor. The manner in which the radiation treatment is given relies upon 
the sort and phase of the tumor being dealt with. In ophthalmooncology field we 
utilize both photon pillar light and furthermore proton beam irradiation.
The metastatic free survival rate, the local control and the late toxicity were 
studied in patients that underwent fractionated Stereotactic Radiation Therapy 
(fSRT) for uveal melanoma. These patients had a median follow-up 32 months 
and were given five fractions of 10 Gy. The results showed that fSRT is an effective 
treatment for uveal melanoma with a good local control. There were performed 15 
enucleations after irradiation mainly because of neurovascular glaucoma [16].
Plaque therapy is the most often utilized framework for delivering radiation The 
other methods are Gamma Knife or methods that include proton beam. Radiation 
plaque treatment which offers great tumor control, can frequently safeguard help-
ful vision, and has a fundamental visualization that is practically identical to that of 
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enucleation. Enucleation remains the standard strategy for the board of the biggest 
melanomas of the choroid and ciliary body. The Collaborative Ocular Melanoma 
Study (COMS) is randomized clinical trial assessing essential enucleation versus 
beam radiation done externaly followed by enucleation in the management of 
patients with choroidal melanomas. The study demonstrated that the two options 
to be used in same medium sized tumors. COMS studied also treatment of large 
tumors and found out that combined external radiotherapy followd by enucleation 
shown that there is no limit in orbital recurrence of the tumor mass [10–13].
3.1  One day session stereotactic radiosurgery for uveal melanoma: our 
experience
Stereotactic radiosurgery (SRS) is technically challenging therapeutic irradiat-
ing method. SRS complements or supplies (replaces) classic surgical intervention. 
The purpose of using SRS is single, because high therapeutic irradiation dosage is to 
involve only an exact specified tumor structure, while the other organs and structures 
are contemporary protected. We use special hardware equipment of workstation 
and software. Professional experiences of specialists of various fields (neurosurgeon 
trained in stereotactic radiosurgery, radiation oncologist, ophthalmologist, radiolo-
gist, clinical physicist and registered nurse trained for radiosurgery) are needed.
The surgery is determined by patient preparation before surgery interven-
tion. This consists of processing of health of the patient and whole patients 
imaging documentation. It is important to analyze the patient’s illnesses and 
the patient’s indication by the Indicating Commission (BTB). The Commission 
consists of the members as a neurosurgeon trained in radiosurgery, radiation 
oncologists, ophthalmologists, radiologists and clinical physicists. Just after the 
see the records and imaging of the patients they decides whether to do SRS or 
not. The Progress Committee selects, on the basis of a recommendation on the 
suitability of ophthalmic oncological surgery, which evaluates the suitability of 
conventional surgery, stereotactic radiosurgery, fractional stereotactic radiosur-
gery, intensity modulated radiotherapy (IMRT) or three-dimensional comfort 
radiotherapy (3 D-CRT).
Indicated patients for stereotactic radiosurgical intervention are concerned 
for inpatient care Ophthalmology Department of Faculty of Medicine, Comenius 
University in Bratislava. The whole hospitalization lasts most often three days. The 
patient admission includes interview with the patient with detailed information 
about the course of operation, performance benefits as well as acquaintance with 
potential acute and late postoperative complications (adverse effects), after the 
informed consent is signed by the patient.
Patient’s affirmation in hospital bed department (clinical care) is carried two 
days before the surgery. Clinical examination will be done in detail. The docu-
mentation patient brought is studied, in case there are some missing examinations 
they are done and completed by the time of the surgery and a preoperative phar-
macotherapy treatment in hospital bed department is placed on. One day before 
the stereotactic radiosurgery (SRS) patient has to use premedication. Within the 
preoperative premedication the patient is using the antiedema therapy, which 
intensity depends on the size, location of the lesion and the presence of edema. The 
presented therapy continues at the day of surgery and also the following day.
The patient’s record must incorporate the age at treatment, volume and size of 
tumor, the most extreme stature of the tumor estimated by A, B scan ultrasound. 
The presence and the degree of secondary retinal detachment, and note if there is 




patient straightforwardly after computer CT and MRI assessment is determined as 
the progression of SRS strategy and is included to the scheme of stereotactic planning.
Mechanical fixation to the stereotactic (Leibinger) frame is done before ste-
reotactic irradiation immobilization of the affected eye. Stiches are put under 4 
direct extraocular muscles through conjunctiva and through the upper and lower 
lid. The stereotactic frame is fixed to the head and the stiches are attached to the 
stereotactic frame on the side of affected eye. The patient undergoes a CT examina-
tion with the eye tied to the patient’s frame. After fixation and administration of the 
drug contrast agent, the examination is performed on one-millimeter scans. After 
completing the CT examination, the patient is transferred to an MRI examination. 
The patient undergoes an MRI examination with the eye still fixed on a stereotactic 
frame. After placement in the MRI, a contrast agent is administered. MRI and CT 
imaging records are sent to a computer console in the computer room.
At that point after the CT and MRI examinations patient is transported to the 
resting room of Department of radiotherapy of St. Elizabeth Oncological Institute 
and is waiting for exposure in the linear accelerator.
Clinical physicist processes imaging records for the purpose of fusion and sub-
sequent planning of stereotactic radiosurgery irradiation. By the fusion of images 
obtained from the CT and MRI it is obtained an accurate image and the structure-
relationship of operated patient. CT examination does not always perfect morphol-
ogy image of targeting and risk structures, but it is an accurate and does not distort 
the displaying structures. MRI can distort displaying targeted and risk structures, 
particularly in the area of bone structures arises the distortion. Neural structures 
are showed in three dimensions, which allows a reconstruction and good distinc-
tiveness of targeted and risk neural structures. Planning system communicates only 
with the CT imaging, in which information is transmitted from other investigating 
modalities. Clinical physicist makes by the fusion the correction of the treating 
volume of a focus and risk structures from the MRI records to CT imaging.
After imaging the target and risk structures, the neurosurgeon draws the 
target volumes and risk structures in sections of one millimeter in a CT record and 
consults them with an ophthalmologist and radiologist. The planning of stereotactic 
treatment after the fusion of CT and MR is optimized according to the critical 
structures, which are the lens, the optic nerve on both sides, and chiasma is also 
marked as the critical structure.
The best plan is after applied for therapy at linear accelerator. Calculation of 
tumor volume depends on the ROI (region of interest) of the tumor and 3D recon-
struction is done. The planned therapeutic dose is 35.0 Gy by 99% of DVH (dose 
volume histogram). Model LINAC C 600 C/D Varian with 6 MeV X is utilized.
3.1.1 Stereotactic planning
The stereotactic treatment arranging after combination of CT and MRI pictures 
is streamlined by the basic structures - focal point, optic nerve, and furthermore 
focal point and optic nerve at the contralateral side, chiasm.
The planned therapeutic dose in SRS is 35.0 Gy, TDmin. The dose varies from 
35.0 to 38.0 Gy, TDmax 37.0–50.0 Gy to the margin of the lesion. We use PTV 
(treatment volume planning) at least 95% isodose planning. Doses for critical 
structures such as the optic nerve and optic disc are less than 8.0 Gy and 10.0 Gy for 
the anterior segment of the eye (Figures 1 and 2).
The clinical physicist embeds the plan into the verification system after printing 
the radiation parameters and documentation. At the same day after the planning is 
finished the patient undergoes irradiation at linear accelerator in the afternoon.
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Mechanical fixation to the stereotactic frame ensures that the head while the 
examination and treatment is in the same, right position. Along with the merger of 
images from CT and MRI is guaranteed the accuracy of the method in the order of 
tenths of a millimeter.
When the exposure id completed the patient is unfixed from the operating table 
and moved into the operating room. According to volume and collimators the whole 
procedure lasts from 15 to 50 minutes.
In the case of application of stereotactic radiosurgery using micro-multileaf col-
limator makes clinical physicist verification plan using the verification phantom. He 
inserts the irradiation plan of patient into verification system of linear accelerator 
and verifies the accuracy of irradiation plan applications into verification phantom 
by irradiation of verification phantom by the dosimetric system.
Figure 1. 
Stereotactic planning scheme for patient with uveal melanoma on linear accelerator (TD – 35.0 Gy) – Part a. 
origin: Dept. of stereotactic radiosurgery, Bratislava.
Figure 2. 
Stereotactic planning scheme for patient with uveal melanoma on linear accelerator (TD – 35.0 Gy) – Part B. 




3.1.2 Stereotactic radiosurgery for uveal melanoma: Our results
Treatment of uveal melanoma in Slovakia is performed on direct quicken-
ing agent LINAC. One-fraction LINAC radiotherapy/radiosurgery is an unusual 
approach to treatment of choroidal melanoma. Hypofractionation with a broad 
shoulder in linear-quadratic model for radioresistant tumors like choroidal mela-
noma is still in discussion.
We evaluated in our study local failure which leads into enucleation as an end 
point in patients treated by SRS with long-term follow-up having accrued at the 
time of analysis. We evaluate in our study the treatment of posterior uveal mela-
noma by one-day session of LINAC stereotactic radiosurgery.
The first goal of our study was to evaluate treatment BCVA decline in patients 
who has posterior uveal melanoma treated with SRS in 6 months interval 24 months 
after SRS.
The second goal was to find out whether the group of patients with better initial 
visual acuity on the beginning of treatment would have also a better chance to pre-
serve vision. The observed after-treatment decline in BCVA was 24 months interval 
after the treatment.
The third goal was observation of the tumor regression by the maximum eleva-
tion measurement using B-scan ultrasound in the group of patients with single 
irradiation (SRS) in interval 1 and 2 years after the treatment.
For patients treated by SRS in the period 2001–2008 was a retrospective analysis 
was undertaken. At the Department of Ophthalmology, Comenius University 
in Bratislava we reviewed 84 patients records with choroidal melanoma or with 
ciliary body melanoma treated in this period. 44 patients underwent primary 
enucleation (52.4%) out of 84 patients and 40 patients underwent SRS as an initial 
treatment (47.6%). The diagnosis was established on the basic of ophthalmologi-
cal examination, ultrasound, CT or MRI examination. Excluded from analyzed 
cohort were metastatic intraocular tumors, juxtapapillary localized tumors and 
melanocytomas.
Each patient record must have details such as the age at treatment, tumor size, 
tumor volume, the maximum height of the tumor by A, B scan ultrasound, the 
presence and the extent of secondary retinal detachment, and if there are signs of 
extrascleral spread.
The tumors were divided into 3 groups as follows: small up to 4 or 5 mm of 
maximal elevation, middle 4–8 mm, and large over 8 mm.
In the group of one stereotactic irradiation, an increase in the tumor was 
observed in a 6-month interval by ultrasound with a B-scan ophthalmologist. We 
compared tumor regression by measuring maximal elevation using B-scan ultra-
sound in a group of 25 patients with single irradiation (SRS) at 12 and 24 months 
post-treatment.
3.1.3 Enucleation versus stereotactic radiosurgery: Our results
We analyzed the treatment outcome and possible survival difference between 
radical surgical treatment (primary enucleation) and stereotactic radiosurgery 
(SRS) at the Department of Ophthalmology, Comenius University in Bratislava, in 
patients with posterior uveal melanoma.
Patients treated for uveal melanoma in posterior during the period 2001–2008 
are analyzed in the study. The goal of the study was to compare the relapse-free 
survival in the cohort of patients initially treated by SRS or they primary under-




We analyzed each patient’s record with ciliary body or choroidal melanoma 
treated by enucleation. We divided them into two groups: first group had 44 
patients (52%) using surgical treatment and the second group had 40 patients 
(48%) using SRS treatment. The therapeutic attitude was set up based on ophthal-
moscopy, ultrasound (A, B mode), other ophthalmological findings, visual acuity, 
and general status of each patient and MRI examination. Volume of the tumor was 
determined by using the formula:
 Tumor volume length width height
6
π
= ∗ ∗ ∗  (1)
 ( ) ( )10 10
0,30103* number of months
Td = 
log final volume  – log starting volume  (2)
The disease-free interval was defined as the period from treatment (either 
enucleation or SRS) until the development of metastasis, or the death of the patient. 
The patients after enucleation were examined by ophthalmologist every six months, 
with a monthly interval in the first six months, dependent on problems with using 
individual prosthesis. The patients after stereotactic radiosurgery were examined 
by an ophthalmologist every three months: visual acuity, biomicroscopy (slit lamp), 
intraocular pressure, ultrasound in A and B mode, fundus photography and since 
the year 2007 also OCT (optical coherence tomography) was routinely done. Post 
radiation complications and tumor dimension and extent of secondary retinal 
detachment were observed. The patients were observed in the period from 2001 
(01/01) to 2008 (31/12) and the data were analyzed.
The disease-free interval was defined as the time from treatment until the 
development of metastases. Patients were seen in three months interval in the 
first year after the SRS, later in six months interval following SRS. Patients in both 
groups were regularly in six months interval recommended to their oncologist to a 
liver ultrasound, abdominal ultrasound, liver function test, brain CT, chest X-ray to 
confirm or exclude the presence of metastases. In individual cases they were recom-
mended to brain CT or PET/CT.
In the period 2001–2008 a total number of 84 patients with intermediate or large 
uveal melanoma were treated with either radical surgical removal of the whole 
eyeball (enucleation), or SRS. In a group of 40 patients who underwent SRS there 
were 22 male and 18 female - the total median age was 55 years; the median age of 
female was 54 years and 58 years of male. In a group of 44 patients with enucleated 
eyes the median age was 68.5 year. In the group there were 21 males (median age 
64), and 23 females (median age 73). The median tumor volume in group of ste-
reotactic patients was 0,65 cm3 (0,4 - 0,8), in group of enucleated patients 1,1 cm3 
(0,8 - 1,25).
Five patients treated in the first step with SRS required subsequent enucleation 
due to the complications - secondary neovascular glaucoma. Three patients of this 
subgroup underwent pars plana vitrectomy with endoresection of the tumors plus 
silicon oil, but the enucleation was necessary due to the complication - relapse of 
the tumor.
Histopathologically in the group of enucleated eyes after SRS due to complica-
tions in four patients with malignant melanoma of the mixed cell type, in two cases 
an epithelioid type, and in one case a spindle-cell type A was confirmed.
In the group of primary enucleated eyes, there were four findings of an epithe-
lioid-cell type, one case of a nodular type, as well as 10 cases of both, a mixed-cell 




The age and tumor volume are important explanatory variables (termed 
covariates) that are assumed to be associated with survival and need to be incor-
porated in the model. Results on logistic regression confirmed significance of the 
model with the predictors age and tumor volume (P = 0.01). The tumor volume 
was a significant unique predictor (P = 0.035); age with its borderline probabil-
ity value of 0.1 could be assumed as possibly associated with the outcome. The 
estimator of survival rates adjusted for these predictors was constructed based 
on Cox’s regression model which examines the relationship between survival and 
both predictors.
3.1.4 Complications after stereotactic radiosurgery: Our results
The fundamental objective of radioactive therapy is to control malignancy while 
maintaining useful vision. Present techniques result in a high incidence of tumor 
control for intermediate and small lesions (< 8 mm in height). Tumor control for 
enormous sores is not ideal, also, here is a higher frequency of late complexities 
bringing about hindered vision in huge sores. All things considered, radiation por-
tion decrease to the uninvolved piece of the eye will lessen the rate of late difficul-
ties while keeping up a high occurrence of tumor control for more modest tumors.
Utilizing of 3-D radiation dosimetry is accepted that will have significant advan-
tage as far as therapy enhancement and lower frequency of late inconveniences. 
Such a 3-D framework grants exact pre-treatment arranging and adjustments of the 
arrangement at short notification, for example, on account of new intraoperative 
discoveries. There is overpowering proof that threatening melanoma of the uveal 
plot can be dealt with securely with radioactive plaques with long haul endurance 
rates equivalent to those of enucleation. We think, that the vessels around the optic 
plate are harmed by full portion light, prompting retinal ischemia, and this courte-
sies the presence of neovascular glaucoma. Safeguarding of the eye work is normal 
in most of radioactive-plaque treatment treated patients. Utilization of low energy 
isotopes, collimation of individual seeds, and routine utilization of 3-D imaging and 
3-D dosimetry should assist with promoting improve episcleral plaque treatment. 
In writing the rate of post-radiotherapy enucleation from all causes is about 20%. 
The diminishing of the occurrence of intricacies as waterfall, radiation papillitis, 
radiation maculopathy, optional glaucoma is because of extremely exacting signs of 
back uveal melanoma. Today, no randomized planned investigation of the impact of 
the elective moderate medicines for choroidal melanoma on visual result have been 
performed.
In our group of patients after Ru106/Rh106 plaque treatment the accompanying 
late intricacies prompted crumbling of visual keenness and were seen at the last 
subsequent assessment:
• macular pulverization due to scarring around the tumor, optic nerve decay,
• macular degeneration, retinopathy, fractional focal point haziness, complete 
waterfall, glassy discharge, optional glaucoma, apoplexy of the focal retinal 
vein.
The patient will develop radiation cataract if more than 30% of the periphery of 
the lens is irradiated. If the diameter of the tumor is large, invasion of the iris may 
occur, or if the anterior margin of the tumor is well in front of the equator, the lens 
may be more sensitive to irradiation. Post-radiation cataracts can occur even if less 
than 30% of its periphery is irradiated.
Melanoma
14
Our clinical experience shows that auxiliary enucleation after stereotactic 
radiosurgery because of light neuropathy and optional glaucoma was essential just 
in 11.5% in 3 to 5 years stretch after illumination.
3.1.5 Follow-up
The patient after SRS is controlled regularly ambulatory, the clinical and MRI 
examinations are carried out, which are made ambulatory, initially and MRI is con-
trolled after 3 months after SRS, first year, next two years in half yearly intervals, 
then 1 time a year in a following 5 years. Patient is monitored by an ophthalmologist 
in 2 weeks, later 6 weeks and 3 months interval - visual acuity, intraocular pressure, 
slit lamp examination, fundus photo, ultrasound – B-scan, OCT, perimetry. In 
3-months’ interval patient is send to MRI control [2, 17, 18].
4. Discussion
Fifty years back, enucleation was the main acknowledged choice of treatment 
for melanoma, perception until recorded development was supported for little 
tumors that could not be unquestionably analyzed as melanomas on beginning 
introduction. These days with the openness and showed sufficiency of eyeball-
sparing medicines, a conflict can be made for before treatment of these vague les-
sions. Data from the COMS primers reveals that melanoma-related mortality varies 
with tumor size at period of treatment. For medium estimated tumors (portrayed 
as tumors 2.5 to 10 mm in apical height and up to 16 mm in greatest basal width), 
melanoma-express mortality was 10% at five years, and 18% at 10 years. For huge 
tumors (those astounding the size models for medium tumors in either apical height 
or greatest basal expansiveness; or peripapillary tumors with an apical height more 
conspicuous than 8 mm), the rates extended to generally 27% at five years and 40% 
at 10 years. Also, as referenced above, archived development before treatment has 
been demonstrated to be a danger factor for metastasis. In any case, development 
might be a marker for more forceful tumors, and it has not been demonstrated that 
treating these tumors prior diminishes mortality [7].
Our present strategies for radiotherapy consider powerful nearby tumor control 
with eyeball preservation, yet visual morbidity is still high. In this manner, it is 
important to gauge the mortality hazard caused via cautious perception before 
treatment of uncertain sores against the outcomes of visual misfortune actuated by 
treatment.
In a small COMS tumor observation study, there were six melanoma-related 
transitions from a cohort of 67 tumor patients treated after baseline perception. 
Only two of these transitions occurred within five years of enrollment, resulting in 
an inaccurate five-year death rate with an explicit melanoma of 3% [11].
One-portion LINAC radiotherapy/radiosurgery is an abnormal way to deal 
with treatment of choroidal melanoma. Hypofractionation with a wide shoulder 
in straight quadratic model is still in conversation for radioresistant tumors like 
choroidal melanoma. In this examination we assessed nearby disappointment 
prompting enucleation as an end point in patients treated by SRS with long haul 
development having accumulated at the hour of investigation [19].
Picture combination of a differentiation improved attractive reverberation 
imaging (MRI) and figured tomography (CT) is utilized for treatment arranging 
co-ordinates. A few creators incline toward light before enucleation for huge uveal 
melanoma. This treatment is utilized in a method of SRS with a solitary division 




Because of our outcomes the saw after-treatment decrease in BCVA was not 
emphatically connected with higher pervasiveness of better BCVA before SRS, 
however the anatomical outcome after the treatment was at any rate anatomically 
saved eyeball [17].
Empowering our outcomes legitimize further examinations to assess one day 
meeting method and its viability as an option in contrast to other light helpful meth-
odologies. On the off chance that we utilized single SRS treatment just, in patients 
with tumor volume over 0.6 cm3 the danger of relapse was high, over half and extra 
treatment was essential. As per our experience the portion of 35.0 Gy is not adequate 
light and may cause backslide just in patients with high volume tumors, over 0.6 cm3. 
By breaking down individual patient’s consequences of this examination, we pre-
sume that this treatment is adequate for little and middle of the road tumors with the 
rise not more than 6 mm, resp. volume up to 0.4 cm3 as per individual stereotactic 
arranging plan of every patient as a solitary treatment system. Auxiliary enucleation 
after stereotactic radiosurgery due to mild neuropathy and secondary glaucoma was 
vital in only 11.5% at 3 to 5 years after illumination. In our examination, proximal 
tumor control was effective in 95% of patients at 3 years after stereotactic radiosur-
gery and in 85% of patients at 5 years after stereotactic radiosurgery [20].
As indicated by our outcomes one-day session SRS with 35.0 Gy is adequate to 
treat little and center stage melanoma. No endurance distinction inferable from 
stereotactic light or consolidated and surgical attitude - enucleation of uveal mela-
noma has been exhibited in the review concentrate in Slovak Republic. Enucleation 
after SRS in 7 patients was in stretch 6 months to two years after SRS. A little 
distinction is conceivable, yet a clinically significant contrast in death rates, regard-
less of whether from all causes or from metastatic melanoma, is improbable.
A high degree of local control can be achieved with a five-year control rate 
exceeding 95% in patients treated with charged particles. Radiotherapy with a 
62 MeV proton rod with a cyclotron achieves a high rate of close tumor control 
and visual protection, with the visual outcome depending on the size and area of 
the tumor.
Huge, imminent, randomized preliminaries were intended to look at mortality 
figures for medium-sized melanomas treated by brachytherapy or enucleation. The 
outcomes could not show the distinction in death rates between the two treatment 
bunches following a limit of 12 years of development.
In the most recent years, the administration of patients with uveal melanoma has 
changed toward eyeball saving strategies. Options other than extreme enucleation 
range from perception to perception to transpupillary thermotherapy, block-extrac-
tion, endoresection with standards plana vitrectomy, brachytherapy utilizing an 
assortment of radioisotopes, outside bar radiotherapy, charged particles and stereo-
tactic radiosurgery or strategies can be approached. SRS has recently been proposed 
as an optional treatment for posterior uveal melanoma. Treatment for each patient 
should be selected according to the patient’s general condition, stage and nature of 
the tumor. COMS is planned to provide remote information on regular history as 
well as a useful speech.
Single-division stereotactic radiosurgery is normally finished with a Gamma 
Knife just as more as of late with a CyberKnife. The remedial single portion has 
been diminished to as low as 35.0 Gy in the course of recent years without decrease 
in tumor control. Dosages of 40.0 Gy conveyed at the half isodose bring about 
great nearby tumor control and satisfactory harmfulness. Since radiobiological 
contemplates show a potential favorable position of hypo fractionated treatment 
over a solitary huge portion to clean uveal melanoma cell lines, fractionated stereo-
tactic radiotherapy (SRT) has increased extra interest. Other than expanded tumor 
control, poisonousness ought to hypothetically be diminished by fractionation. 
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Direct quickening agents (LINAC) have the upside of an attainable fractionation. 
Most LINAC contemplates utilize a hypo fractionated plan of 4–5 portions and 
complete dosages somewhere in the range of 50.0 and 70.0 Gy. The viability of 
SRT for uveal melanoma has been demonstrated in various investigations with 
neighborhood tumor control rates announced over 90%, 5 and 10 years after 
treatment. Radiogenic results after SRT are accounted for also to different types 
of radiotherapy, with waterfall advancement, radiation retinopathy, opticopathy 
and neovascular glaucoma being liable for most of optional vision misfortunes and 
auxiliary enucleations. Generally speaking, stereotactic photon bar radiotherapies 
(SRS and SRT) are viewed as compelling treatment modalities for uveal melanoma, 
with promising late tumor control and poisonousness rates. SRS is a generally new 
strategy, so there is a requirement for multi-focus preliminary to contrast the results 
following stereotactic radiosurgery and different techniques. Nonetheless, as of 
recently, no investigation has been acted in this point. Studies contrasting endur-
ance rates following enucleation versus more current treatment modalities, includ-
ing SRS, recommended comparative rates for tantamount sores and in light of the 
fact that revealed nearby tumor control rate following SRS seem similar, we offer 
SRS to patients who might somehow or another require enucleation [1].
Stereotactic photon treatment of uveal melanoma, in light of CT and MRI pic-
tures, is a protected and exact treatment choice. Neighborhood control was discov-
ered to be superb. Due to choice models, the quantity of patients in the investigation 
with decreased visual sharpness will likely expansion later on.
Neighborhood power over 95% shows up in certain investigations: in the 
investigation of Dieckmann nearby control is 98% after a middle perception time 
33 months follow up. The perception time is still too short to even consider allowing 
complete ends, yet their outcomes are tantamount with the 82–98% nearby control 
rate detailed by different gatherings after a middle perception season of as long as 
15 years [21].
Visual misfortune after proton pillar light was depicted in 33–47% following 1 
and 2 years, individually, for tumors situated close to the optic plate and fovea.
Different creators announced in a review study that light of 30.0 Gy of in excess 
of 2 mm of the optic nerve head started an optic neuropathy.
In the investigation of Dieckmann because of troublesome tumor size and 
area in the region of basic structures, for example optic nerve and macula, visual 
decrease was seen in a high number of the patients. After a perception season of 
beyond what a half year visual sharpness can be assessed in 79 patients. In the gath-
ering of 77 patients 85.5% gave visual sharpness of 0.1 or better before radiotherapy. 
LINAC based stereotactic light for melanoma of uvea is plausible and all around 
endured. Can be offered to patients with medium measured and horribly found 
melanoma of uvea who are looking for an eye-protecting therapy [22].
To accomplish great visual keenness result it is significant right limitation of the 
tumor. Brachytherapy Ru106 of back choroidal melanoma accomplishes great pres-
ervation of vision if the tumor does not stretch out near the optic nerve or fovea. 
Realize that the intensity of a test to look at endurance in at least two gatherings 
is connected not to the all out example size but rather to the quantity of functions 
of interest, (for example, passing for this situation). At the end of the day, the 
endurance tests perform better when the editing is not excessively substantial, and, 
specifically, when the example of controlling is comparable over the various gather-
ings. High number of right-blue-penciled information (from those patients who 
actually were alive toward the finish of perception, or exited the investigation for 
different reasons other than death before its end) could influence the unwavering 
quality of the outcomes. Subsequently, the substantial controlling may confuse the 




subjects uncovered (in danger) at later occasions, decreasing the successful example 
sizes. Also, little example sizes may additionally expand the impact of the presump-
tion infringement. It is not sensible, notwithstanding, to drop the chose informative 
variable(s) from the model, since there are “genuine world” reasons why these 
specific factors ought to stay in the last model [23].
To this date, no preliminary examination of the dosimetry, safety and viability 
of SRS or evaluation of gamma knife radiosurgery results for melanoma has been 
performed. So far information from several reported cases recommends that SRS 
can have comparable close tumor control rates, metastases, death rates and involve-
ment rates brachytherapy. Late examinations recommend that gamma knife radio-
surgery and SRS may be an appropriate choice for the treatment of uveal melanoma 
in those patients in whom ulcers are not suitable for conventional brachytherapy. 
The findings in the setting recommend a part of SRS in the treatment of selected 
cases of uveal melanoma [24].
Entanglements after specific techniques can prompt auxiliary neovascular 
glaucoma and may result to the enucleation, that is the reason the eye maintenance 
is one of the fundamental objectives of the moderate treatment. A multivariate 
information investigation by utilizing the directed learning methods, specifically 
the calculation known as Regularized Least Squares (RLS) was utilized in investiga-
tion of Mosci. Their examination was the biggest one in Italy and they exhibited the 
brilliant neighborhood tumor control, endurance and eye consistency standard after 
the proton shaft light treatment. As their results suggest, further improvements in 
treatment delivery may be important in determining visual outcomes and complexi-
ties after proton shaft therapy in visual melanoma dosing and delivery [25].
The basic problems of radiotherapy in one meeting are the effects of propaga-
tion and hypofractionation of the part. The size and area of the tumor, for example 
closer than 2 mm from the optical plate, are the main components for determining 
the clinical evaluation of the visual acuity result.
Distinguishing proof of danger variables may lessen the paces of repeat and 
lead to less inconveniences, safeguarding of the eye, improved visual capacity 
and, conceivably, better endurance result. Repeat of optic neuropathy after ste-
reotactic radiosurgery is an issue by intraocular tumors as well as for example by 
perichiasmal tumors stereotactic illumination. Albeit uncommon, optic neuropathy 
may follow radiosurgery to injuries close to the visual pathways. Cautious portion 
arranging guided by MRI with limitation of the maximal portion to the visual path-
ways to under 8.0 Gy will probably diminish the frequency of this entanglement.
Similar issues with visual sharpness misfortune as in stereotactic radiosurgery 
are found in patients after other radiotherapy methods, for example brachytherapy. 
In the sequential arrangement of patients after Ru106 brachytherapy, patients held 
some helpful vision in the principal postoperative years and a couple even improved 
visual sharpness, notwithstanding, the drawn out visual result is poor with a 
proceeding with visual keenness misfortune over the long run. Countless patients 
became visually impaired or lost perusing capacity following 5 years, either due to 
radiation confusions or auxiliary enucleation.
Stereotactic radiosurgery and fractionated stereotactic radiotherapy have 
developed as promising, non-intrusive medicines for uveal melanoma [26]. Albeit, 
verifiably, melanoma has been viewed as a moderately radioresistant tumor, 
fresher information have tested this perspective, and radiation treatment is cur-
rently viewed as a helpful segment of the restorative armamentarium for harmful 
melanoma. As indicated by our outcomes a solitary one-day meetings SRS with 35.0 
Gy is adequate to treat little and center stage melanoma. No endurance distinction 
inferable from stereotactic light or joined and careful mentality - enucleation of 
uveal melanoma has been exhibited in the review concentrate in Slovakia.
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In our examination bunches researched, endurance investigation changed for 
indicators demonstrated that the gathering of patients after stereotactic radiosur-
gery had similar result as the gathering of patients treated with extremist medical 
procedure. In light of our examination, we expect that the endurance guess is 
basically dictated by the personality of the tumor in relationship to the status of 
the patient. Clinically, the main factors that influence the metastatic cycle are the 
limitation and size (volume) of the sore.
There has been played out no multicenter preliminary to survey dosimetry, 
wellbeing and adequacy of SRS, or to assess results of gamma knight radiosurgery 
for melanoma yet, yet information from a few announced case arrangement 
recommend that SRS could have comparative nearby tumor control rate, metastasis 
rate, death rate and intricacies rate when contrasted with brachytherapy. Late 
investigations have proposed that gamma knight radiosurgery and SRS might be 
a fitting option for treating uveal melanoma in those patients, in whom sores are 
ineligible for customary brachytherapy. The discoveries in the arrangement propose 
a part of SRS in the treatment of chose instances of uveal melanoma. Treatment 
by either essential enucleation or SRS as per our outcomes does not seem to impact 
the improvement of metastases in patients with uveal melanoma; the endurance 
anticipation is basically controlled by the stage and character of the tumor.
No endurance contrast inferable from stereotactic light or extremist careful dispo-
sition - enucleation of uveal melanoma has been shown in this review study. A little 
contrast is conceivable, yet a clinically significant distinction in death rates, regardless 
of whether from all causes or from metastatic melanoma, is far-fetched. SRS is a 
non-intrusive option in contrast to enucleation in the treatment of uveal melanoma 
with a high tumor control. There is a requirement for multi-focus preliminaries to 
think about the results following stereotactic radiosurgery in treatment of uveal 
melanoma.
5. Conclusion
The single light of the tumor itself is another methodology – it has been 
appeared to accomplish ultrasonic tumor relapse along these lines to brachytherapy. 
SRS of extracerebral sores like uveal melanoma has been developed over the most 
recent twenty years and is an elective treatment for center and enormous back 
choroidal melanoma. With plaque radiotherapy, eye rescue is accomplished, and 
especially for cases in which the tumor is found away from the optic circle or 
macula, helpful vision can be held after treatment.
As indicated by the creators experience dependent on consequences of their 
exploration aftereffects of the adequacy of LINAC-based stereotactic radiosurgery 
treatment in addition to joined strategies in patients with back uveal melanoma in 
stage T2/T3, the stereotactic radiosurgery is a successful strategy to treat middle 
of the road phase of uveal melanoma. At last, one-venture LINAC-based SRS with 
a solitary portion 35.0 Gy can treat patients with center back uveal melanoma and 
save the eyeball or be the initial step of consolidated strategies: illumination before 
endoresection or cyclectomy.
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